Compare Cytokinetics Inc (CYTK) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Sprott Uranium Miners ETF — how do they compare? Cytokinetics Inc trades at $76.34 (market cap $10.63B), while Sprott Uranium Miners ETF trades at $55.7. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | URNM | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $87.26 | $83.99 |
52-Week Low | $34.31 | $44.14 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
URNM trades at $55.97, up 2.51% today, with a bullish technical signal driven by moving averages. The ETF focuses on uranium miners, benefiting from nuclear energy's resurgence. Recent news highlights significant government funding and AI-driven power demand as catalysts. Key support is at $55, with resistance at $56.
The outlook is positive due to structural uranium supply deficits and growing nuclear adoption, but risks include volatility from spot price swings and concentrated miner exposure. Analyst sentiment is mixed, with some favoring pure-miner exposure while others caution on valuation gaps versus underlying uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
